The impact of trimetazidine treatment on left ventricular functions and plasma brain natriuretic peptide levels in patients with non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention

Korean Circulation Journal

Volumn 43, Issue 7, 2013, Pages 462-467

  Demirelli, Selami ^a   Karakelleoǧlu, Şule ^b   Gündoǧdu, Fuat ^b   Taş, Muhammed Hakan ^b   Kaya, Ahmet ^c   Duman, Hakan ^d   Deǧirmenci, Hüsnü ^e   Hamur, Hikmet ^f   Şimşek, Ziya ^b  

^a Erzurum Regional Training and Research Hospital   (Turkey)

^b ATATURK UNIVERSITY   (Turkey)

^c ORDU UNIVERSITY   (Turkey)

^d Rize Devlet Hastanesi   (Turkey)

^e Erzurum Palandoken Government Hospital   (Turkey)

^f Mengücekgazi Training and Research Hospital   (Turkey)

Author keywords

Natriuretic peptide, brain; Percutaneous coronary intervention; Trimetazidine

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TRIMETAZIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART PERFORMANCE; HUMAN; LOADING DRUG DOSE; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84883244403     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2013.43.7.462     Document Type: Article

References (19)

1. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001;22:2267-74. (Pubitemid 34000982)
2. Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart. J Mol Cell Cardiol 1998;30:A112.
3. Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol 1993;21:128-35. (Pubitemid 23006637)
4. American Heart Association. 1999 heart and stroke statistical update. Chicago: American Heart Association; 1999.
5. Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. W Engl J Med 2000;342:1163-70. (Pubitemid 30211047)
6. Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2006;98:14J-8J.
7. Marazzi G, Wajngarten M, Vitale C, et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. Int J Cardiol 2007;120:79-84. (Pubitemid 47002010)
8. Nakamura S, Naruse M, Naruse K, et al. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am J Hypertens 1991 4:909-12.
9. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-9. (Pubitemid 23040916)
10. White HD, French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2003;42:1917-20. (Pubitemid 37485565)
11. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40:437-45. (Pubitemid 34833157)
12. Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004;20:1447-54. (Pubitemid 39361348)
13. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8. (Pubitemid 30165050)
14. Banach M. The role of trimetazidine in the treatment of heart diseases. Ponzan, Poland: Termedia Publishing ouse;2006. p.52-6.
15. Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of denosine plasma levels after oral trimetazidine: a pharmacological preconditioning? Pharmacol Res 2002;45:69-72. (Pubitemid 35425515)
16. López N, Varo N, Díez J, Fortuño MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res 2007;75:536-45. (Pubitemid 47080972)
17. Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs 2002;11:615-29. (Pubitemid 34520613)
18. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992-8. (Pubitemid 44292461)
19. Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovase Drugs 2007;7:143-50. (Pubitemid 46790270)